Merck Sharp + Dohme Corp.

Merck + Co., Inc.

John E Stelmach

Emma R Parmee

Keith Rosauer

Subharekha Raghavan

Shouwu Miao

Ronald M Kim

James R Tata

Cameron James Smith

Linda Brockunier

Yi-Heng Chen

Xibin Liao

Jiang Chang

Jian Guo

Joie Garfunkle

Alan Whitehead

James B Doherty

Songnian Lin

Rui Liang

Yong Zhang

Guoqing Li

Jianmin Fu

Darby Schmidt

Christopher Joseph Sinz

Swaminathan R Natarajan

Rui Zhang

Jonathan A Groeper

Raphaelle Berger

Gang Ji

Amy R Bittner

Falong Jiang

Hong-Dong Li

Hong Shen

Kathleen M Rupprecht

Peter J Sinclair

Jianming Bao

Sherman Tim Waddell

Deping Wang

Philippe G Nantermet

Fa-Xiang Ding

Christopher S Burgey

Mark E Layton

Liangqin Guo

Thomas J Greshock

Anthony J Roecker

Rajan Anand

James J Mulhearn

Hong Li

Meng-Hsin Chen

Fengqi Zhang

Walter Won

Ting Zhang

Gang Zhou

Edward Metzger

Libo Xu

Julianne A Hunt

Tianying Jian

Joung L Goulet

Luping Liu

Olga Ornoski

Xiaoqing Han

Florida Kallashi

David D Wisnoski

Roman Kats-Kagan

Xingfang Hong

Christian P Stevenson

Rowena D Ruzck

Keith G Rosauer

Olga A Ornoski

Darby Rye Schmidt

Linda L Brockunier

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and Rto Rare defined herein, which compounds have properties for blocking Na1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A or their salts, and methods of treating cough, itch, acute pain and neuropathic pain disorders using the same. 

Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Soluble guanylate cyclase stimulators

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver. 

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I. 

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds

Glucagon receptor antagonist compounds of formula I are disclosed: The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation 

(Halo-benzo carbonyl)heterobi cyclic p38 linase inhibiting agents

(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents

Growing community of inventors

Westfield, NJ, United States of America

John E Stelmach